Anlotinib

Generic Name: Anlotinib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₂₂FN_₃O_₃

CAS Number: 1058156-90-3

Unique Ingredient Identifier: GKF8S4C432

Background: Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.

Indication: 用于治疗非小细胞肺癌、结直肠癌、肾癌、软组织肉瘤、甲状腺癌、胃癌等。

用于无法手术的局部晚期或转移性甲状腺髓样癌患者的治疗。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Anlotinib
Drug: Penpulimab

First Posted Date: 2021-07-21

Last Posted Date: 2022-03-08

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 32

Registration Number: NCT04970914

Locations: 🇨🇳
Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
China-Japan friendship hospital, Beijing, Beijing, China
🇨🇳
Hebei Petro China Central Hospital, Langfang, Hebei, China

and more 5 locations

Anlotinib for Esophageal Cancer (AFEC)

Conditions: Esophageal Cancer

First Posted Date: 2021-07-19

Last Posted Date: 2021-07-19

Lead Sponsor: Anyang Tumor Hospital

Target Recruit Count: 200

Registration Number: NCT04966611

Locations: 🇨🇳
Anyang Cancer Hospital, Anyang, China

Trametinib Plus Anlotinib in Non-G12C KRAS-Mutant NSCLC Patients

Phase 1

Completed

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Trametinib
Drug: Anlotinib

First Posted Date: 2021-07-19

Last Posted Date: 2024-04-23

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 33

Registration Number: NCT04967079

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

TISLELIZUMAB Combined With Anlotinib and Chemotherapy(XELOX) in the Treatment of Advanced Gastric Carcinoma

Phase 1

Conditions: Gastric Cancer

Interventions: Drug: BGB-A317
Drug: Anlotinib
Drug: Oxaliplatin
Drug: Capecitabine

First Posted Date: 2021-07-15

Last Posted Date: 2021-07-15

Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University

Target Recruit Count: 66

Registration Number: NCT04963088

Locations: 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, China

Anlotinib for Hepatocellular Carcinoma

Conditions: Liver Neoplasms

First Posted Date: 2021-07-08

Last Posted Date: 2021-07-08

Lead Sponsor: Guangxi Zhuang Autonomous Region People's Hospital

Target Recruit Count: 200

Registration Number: NCT04954521

Locations: 🇨🇳
People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China

Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

Phase 2

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Fluzoparil
Drug: Anlotinib

First Posted Date: 2021-06-21

Last Posted Date: 2021-06-21

Lead Sponsor: Liu Zhenhua

Target Recruit Count: 50

Registration Number: NCT04933175

Locations: 🇨🇳
Liu Zhenhua. ZhuangWu, Fuzhou, Fujain, China

A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative Breast Cancer

Phase 2

Recruiting

Conditions: Triple-negative Breast Cancer

Interventions: Drug: AT regimen
Drug: Tislelizumab
Drug: Anlotinib

First Posted Date: 2021-06-04

Last Posted Date: 2024-01-22

Lead Sponsor: Sichuan Provincial People's Hospital

Target Recruit Count: 32

Registration Number: NCT04914390

Locations: 🇨🇳
Department of breast surgery, Sichuan Provincial People's Hospital, Chengdu, Sichuan, China

Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases in NSCLC

Completed

Conditions: Stereotactic Body Radiation Therapy

Interventions: Drug: Anlotinib

First Posted Date: 2021-06-03

Last Posted Date: 2021-06-03

Lead Sponsor: Peking University Third Hospital

Target Recruit Count: 30

Registration Number: NCT04912128

Locations: 🇨🇳
Department of Radiation Oncology Cancer Center, Peking University Third Hospital 49# North Garden Rd.,Haidian Dist., Beijing, Beijing, China

Furmonertinib Combined With Anlotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Phase 2

Recruiting

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Furmonertinib
Drug: Anlotinib

First Posted Date: 2021-05-20

Last Posted Date: 2023-01-06

Lead Sponsor: Shanghai Chest Hospital

Target Recruit Count: 40

Registration Number: NCT04895930

Locations: 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Phase 2

Recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Sintilimab
Drug: Anlotinib
Drug: Nab paclitaxel
Drug: Carboplatin
Drug: Epirubicin
Drug: Cyclophosphamide

First Posted Date: 2021-05-07

Last Posted Date: 2023-11-08

Lead Sponsor: Guangdong Provincial People's Hospital

Target Recruit Count: 31

Registration Number: NCT04877821

Locations: 🇨🇳
NeoSACT, Guangzhou, Guangdong, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy